Liposomal Doxorubicin Market Size, Share, Growth Analysis, By Product(J7J (Doxil/Caelyx), Sun Pharma (Lipodox), and Teva (Myocet)), By Application(leukemia, bone sarcoma, breast cancer, gastric cancer), By Region - Industry Forecast 2024-2031

Global Liposomal Doxorubicin Market size was valued at USD 1.27 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 2.16 billion by 2031, growing at a CAGR of 6.1% in the forecast period (2024- 2031).

The market for liposomal doxorubicin is growing at a significant rate owing to the increased prevalence of sarcoma. Doxorubicin (liposomal) treats breast cancer, ovarian cancer, Kaposi sarcoma, and other malignant tumours. Doxorubicin is an anti-cancer chemotherapy medication in a liposome, a closed lipid sphere. Factors augmenting the growth of this global market include modern healthcare facilities, rising healthcare costs, improved patient awareness of potential therapies, and the rise in generic versions of life-saving medications. However, the increasing generic medication competition and strict FDA requirements for new drug approval could restrain the worldwide liposomal doxorubicin market.

Furthermore, the market would develop profitably due to increased awareness of adequate medicine substitutes and growing investments by public and private key manufacturers. Sales of liposomal doxorubicin are projected to increase significantly due to the failure of earlier systemic treatment for ovarian cancer and Kaposi's sarcoma associated with AIDS. Hepatocellular carcinoma incidence and survival rates are rising, another factor influencing liposomal doxorubicin demand.

US Liposomal Doxorubicin Market is poised to grow at a sustainable CAGR for the next forecast year.